|Articles|October 25, 2018

8 Quick Qs on Rheumatoid Arthritis

Answer these 8 questions to test your knowledge of the latest RA research findings.

A roundup of the latest rheumatoid arthritis (RA) research findings appeared recently on this site. Take the following 8-question quiz to test your knowledge of these findings.

Question 1:

For more information on all questions and answers, please see 8 New Things in Rheumatoid Arthritis.

Join thousands of clinicians staying current on new therapies, trial data, and expert insights—subscribe to Rheumatology Live today.

Related to this article

September 23rd, 2026

Upadacitinib Approved for Active Polyarticular Juvenile Idiopathic Arthritis in EU

The EC approved upadacitinib for active polyarticular JIA in children 2 years and older, based on phase 1 SELECT-YOUTH efficacy and safety data.

5 Pulmonology Headlines You Missed in August 2026

September 4th, 2026

5 Headlines You Missed in August 2026

August 2026 rheumatology highlights include FDA approval of brepocitinib for dermatomyositis and garetosmab-grts for FOP, and new trial data.

August 6th, 2026

Baricitinib Misses VTE Noninferiority vs TNFi in High-Risk RA

In RA-BRIDGE and RA-BRANCH, baricitinib failed to demonstrate VTE noninferiority in patients with RA enriched for thromboembolic risk factors.

$AB-101 + Rituximab Shows Deep Responses in Refractory RA, SjD, SSc$

July 27th, 2026

AB-101 + Rituximab Shows Deep Responses in Refractory RA, SjD, SSc

A Phase 2a basket trial produced ACR50 responses in 71% of refractory RA patients at 6 months.